Faculty

Back to Index
Michael Pulsipher, MD
Professor of Pediatrics (Clinical Scholar)
Pediatrics
CHLA 4650 W. Sunset Blvd. Off Campus Los Angeles

Publications

Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica. 2017 Mar 24. View in: PubMed

Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2017 Jan 06. View in: PubMed

Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Children with Sickle Cell Disease and Thalassemia: a Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2017 Jan 05. View in: PubMed

CD25 Blockade Delays Treg Reconstitution and Does Not Prevent Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Dec 19. View in: PubMed

A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016 Nov 24; 128(21):2561-2567. View in: PubMed

Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors. J Pediatr. 2016 Nov; 178:164-170. e1. View in: PubMed

HRQoL among Older Related HSC Donors (>60 Yrs. ) is Equivalent to That of Younger Related Donors (18-60 Yrs. ): an RDSafe Study. Biol Blood Marrow Transplant. 2016 Oct 14. View in: PubMed

The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation (HCT): Defining the Unique Late Effects of Children Undergoing HCT for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant. 2016 Oct 10. View in: PubMed

Response to: "Technology and Long-Term Health-Related Quality-of-Life Outcomes in Children with Nonmalignant Disorders after Reduced-Intensity Conditioning and Stem Cell Transplantation". Biol Blood Marrow Transplant. 2016 Sep; 22(9):1734. View in: PubMed

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. Biol Blood Marrow Transplant. 2016 Aug 30. View in: PubMed

Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biol Blood Marrow Transplant. 2016 Aug; 22(8):1467-72. View in: PubMed

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biol Blood Marrow Transplant. 2016 Jul; 22(7):1197-205. View in: PubMed

Research involving pediatric stem cell donors: A way forward. Clin Trials. 2016 Jun; 13(3):304-10. View in: PubMed

European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards. Biol Blood Marrow Transplant. 2016 Mar; 22(3):514-9. View in: PubMed

Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. Biol Blood Marrow Transplant. 2016 Mar; 22(3):520-7. View in: PubMed

Fishing for complements. Blood. 2016 Feb 25; 127(8):957-8. View in: PubMed

Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biol Blood Marrow Transplant. 2016 Feb; 22(2):248-57. View in: PubMed

Evolving hematopoietic stem cell transplantation strategies in severe aplastic anemia. Curr Opin Pediatr. 2016 Feb; 28(1):3-11. View in: PubMed

Deficient Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplantation. Front Immunol. 2016; 7:250. View in: PubMed

Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. Biol Blood Marrow Transplant. 2016 Jan; 22(1):96-103. View in: PubMed

Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2154-9. View in: PubMed

Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients. Cytotherapy. 2015 Dec; 17(12):1667-74. View in: PubMed

Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2052-60. View in: PubMed

Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. Br J Haematol. 2015 Nov; 171(3):411-6. View in: PubMed

Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer. 2015 Oct 15; 121(20):3709-16. View in: PubMed

Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1830-8. View in: PubMed

Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015 Sep; 2(9):e367-75. View in: PubMed

Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol. 2015 Aug; 170(4):574-83. View in: PubMed

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015 May 28; 125(22):3501-8. View in: PubMed

Long-term outcomes in MPS-IH: throwing stars. Blood. 2015 Mar 26; 125(13):2016-7. View in: PubMed

Will post-transplantation cell therapies for pediatric patients become standard of care? Biol Blood Marrow Transplant. Will post-transplantation cell therapies for pediatric patients become standard of care? Biol Blood Marrow Transplant. 2015 Mar; 21(3):402-11. View in: PubMed

Blood and marrow transplant clinical trials network state of the science symposium 2014. Biol Blood Marrow Transplant. 2015 Feb; 21(2):202-24. View in: PubMed

TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant. 2015 Jan; 21(1):67-73. View in: PubMed

Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2015 Jan; 21(1):165-71. View in: PubMed

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014 Oct 10; 32(29):3249-56. View in: PubMed

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica. 2014 Oct; 99(10):1624-31. View in: PubMed

Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol. 2014 Oct; 134(4):935-943. e15. View in: PubMed

Chimerism versus minimal residual disease monitoring after allogeneic transplantation--when do we act and will intervention improve outcomes? Biol Blood Marrow Transplant. Chimerism versus minimal residual disease monitoring after allogeneic transplantation--when do we act and will intervention improve outcomes? Biol Blood Marrow Transplant. 2014 Oct; 20(10):1461-2. View in: PubMed

Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014 Jul 31; 371(5):434-46. View in: PubMed

Haplo is the new black. Blood. 2014 Jul 31; 124(5):675-6. View in: PubMed

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood. 2014 Jul 10; 124(2):287-95. View in: PubMed

Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014 Jul; 20(7):960-8. View in: PubMed

Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood. 2014 Jun 5; 123(23):3655-63. View in: PubMed

Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer. 2014 Jun; 61(6):1126-8. View in: PubMed

Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood. 2014 May 29; 123(22):3504-11. View in: PubMed

Preventable Infections in Children with Leukodystrophy. Ann Clin Transl Neurol. 2014 May 1; 1(5):370-374. View in: PubMed

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood. 2014 Mar 27; 123(13):2017-25. View in: PubMed

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014 Mar 6; 123(10):1615-20. View in: PubMed

Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J Allergy Clin Immunol. 2014 Mar; 133(3):880-2. e10. View in: PubMed

The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013 Oct; 33(7):1156-64. View in: PubMed

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1340-7. View in: PubMed

Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1279-87. View in: PubMed

Exposure of early pediatric trainees to blood and marrow transplantation leads to higher recruitment to the field. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1399-402. View in: PubMed

Aplastic Anemia & MDS International Foundation (AA&MDSIF): bone marrow failure disease scientific symposium 2012. Leuk Res. 2013 Jul; 37(7):848-51. View in: PubMed

Children's Oncology Group's 2013 blueprint for research: stem cell transplantation. Pediatr Blood Cancer. 2013 Jun; 60(6):1044-7. View in: PubMed

Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. Biol Blood Marrow Transplant. 2013 Jun; 19(6):893-7. View in: PubMed

Better BMT for Hurler syndrome--on the level? Blood. Better BMT for Hurler syndrome--on the level? Blood. 2013 May 9; 121(19):3785-7. View in: PubMed

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013 Apr 20; 31(12):1530-8. View in: PubMed

Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. Biol Blood Marrow Transplant. 2013 Apr; 19(4):569-75. View in: PubMed

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood. 2013 Jan 3; 121(1):197-206. View in: PubMed

National marrow donor program session: donor issues. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S15-9. View in: PubMed

Pediatric-specific guidelines for fever and neutropenia: a catalyst for improving care and focusing research. J Clin Oncol. 2012 Dec 10; 30(35):4292-3. View in: PubMed

Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012 Oct 18; 367(16):1487-96. View in: PubMed

Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012 Aug; 18(8):1265-72. View in: PubMed

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biol Blood Marrow Transplant. 2012 Jul; 18(7):979-81. View in: PubMed

Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant. 2012 Jul; 18(7):1007-11. View in: PubMed

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 2012 Apr 26; 119(17):4083-90. View in: PubMed

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012 Apr; 18(4):505-22. View in: PubMed

A donor's a person, no matter how small. Blood. 2012 Mar 22; 119(12):2705-6. View in: PubMed

National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant. 2012 Mar; 18(3):334-47. View in: PubMed

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: health-related quality of life, functional, and neurocognitive outcomes. Biol Blood Marrow Transplant. 2012 Feb; 18(2):162-71. View in: PubMed

NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivors. Biol Blood Marrow Transplant. 2012 Jan; 18(1):6-15. View in: PubMed

Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1833-40. View in: PubMed

NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1725-38. View in: PubMed

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011 Nov 2; 306(17):1874-83. View in: PubMed

National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction. Biol Blood Marrow Transplant. 2011 Nov; 17(11):1573-84. View in: PubMed

NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges. Biol Blood Marrow Transplant. 2011 Oct; 17(10):1428-35. View in: PubMed

NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: state of the science, future directions. Biol Blood Marrow Transplant. 2011 Oct; 17(10):1424-7. View in: PubMed

There's more to surviving transplant than remission. Pediatr Blood Cancer. 2011 Sep; 57(3):359-60. View in: PubMed

Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica. 2011 Jul; 96(7):942-7. View in: PubMed

Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant. 2011 Mar; 17(3):291-9. View in: PubMed

High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant. High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S137-48. View in: PubMed

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood. 2010 Nov 11; 116(19):4007-15. View in: PubMed

Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1212-21. View in: PubMed

Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood. 2010 Jun 17; 115(24):5097-101. View in: PubMed

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010 Jun 10; 28(17):2859-67. View in: PubMed

Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. Biol Blood Marrow Transplant. 2010 Mar; 16(3):384-94. View in: PubMed

Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1620-7. View in: PubMed

A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol. 2009 Dec; 147(5):691-9. View in: PubMed

Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood. 2009 Sep 24; 114(13):2606-16. View in: PubMed

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood. 2009 Aug 13; 114(7):1429-36. View in: PubMed

Maintenance loses its innocence. Blood. 2009 Jun 11; 113(24):6041-2. View in: PubMed

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009 Apr 9; 113(15):3604-11. View in: PubMed

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009 Apr 2; 113(14):3383-91. View in: PubMed

Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant. 2009 Jan; 15(1 Suppl):62-71. View in: PubMed

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1279-87. View in: PubMed

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008 Oct 20; 26(30):4912-20. View in: PubMed

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008 May 1; 112(9):1992-2001. View in: PubMed

Lower hospital mortality and complications after pediatric hematopoietic stem cell transplantation. Crit Care Med. 2008 Mar; 36(3):923-7. View in: PubMed

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol. 2008 Jan 10; 26(2):211-7. View in: PubMed

A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood. 2007 Dec 15; 110(13):4584-7. View in: PubMed

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007 Oct 1; 110(7):2744-8. View in: PubMed

Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1041-8. View in: PubMed

Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2007 Aug; 48(8):1482-95. View in: PubMed

Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant. 2007 Apr; 13(4):423-32. View in: PubMed

The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant. Am J Clin Oncol. 2007 Apr; 30(2):156-62. View in: PubMed

Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood. 2007 Mar 15; 109(6):2618-21. View in: PubMed

Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol. 2006 Sep 1; 24(25):4150-7. View in: PubMed

High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006 Jun 20; 24(18):2891-6. View in: PubMed

Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer. 2006 Apr; 46(4):414-21. View in: PubMed

Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer. 2006 Apr; 46(4):422-33. View in: PubMed

Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant. 2006 Apr; 12(4):454-65. View in: PubMed

The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol. 2006 Apr; 29(2):189-95. View in: PubMed

Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol. 2006 Jan 1; 24(1):145-51. View in: PubMed

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 1; 23(16):3819-29. View in: PubMed

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant. 2005 Apr; 11(4):272-9. View in: PubMed

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004 Dec 1; 104(12):3535-42. View in: PubMed

Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer. 2004 Oct; 43(5):523-33. View in: PubMed

Successful reduced-intensity allogeneic transplantation utilizing a fludarabine-based preparative regimen in a patient with chronic lymphocytic leukaemia and a history of fludarabine-associated autoimmune haemolytic anaemia. Br J Haematol. 2004 Aug; 126(4):623-4. View in: PubMed

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003 Sep 15; 102(6):2021-30. View in: PubMed

Reduced toxicity and prompt engraftment after minimal conditioning of a patient with Fanconi anemia undergoing hematopoietic stem cell transplantation from an HLA-matched unrelated donor. J Pediatr Hematol Oncol. 2003 Jul; 25(7):581-3. View in: PubMed

Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Marrow Transplant. 2003 Apr; 9(4):266-72. View in: PubMed

Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Int J Hematol. 2002 Aug; 76 Suppl 1:184-9. View in: PubMed

Non-myeloablative hematopoietic cell transplant for treatment of nonmalignant disorders in children. Int J Hematol. 2002 Aug; 76 Suppl 2:271-7. View in: PubMed

Powered bySC CTSI